Home » Cardiovascular » ATLAS ACS-2: Rivaroxaban after ACS

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

ATLAS ACS-2: Rivaroxaban after ACS

The ATLAS ACS-2 trial tested the use of rivaroxaban in addition to standard dual antiplatelet therapy in patients with acute coronary syndrome. The results showed a reduction in the composite of CV mortality, recurrent MI, and stroke, but increased the risk of nonfatal bleeding.

2012, ATLAS ACS-2 Trial Visual Abstract: Rivaroxaban after ACS, NEJM

Subscribe via email